文献速递炎症性肠病

生物制剂和小分子药物在中重度溃疡性结肠炎中的疗效:系统评价与网状Meta分析

Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis.
PubMed 文献 · Gut · 2021-12-22

该系统评价与网状Meta分析检索至2021年10月的文献,纳入28项试验共12504例患者,比较生物制剂和小分子药物在中重度活动性溃疡性结肠炎中的相对疗效与安全性。结果显示,乌帕替尼45 mg每日一次在临床缓解方面排名第一,英夫利西单抗10 mg/kg在内镜改善方面排名第一。多数药物安全且耐受良好。

要点

  • 乌帕替尼45 mg每日一次在全部患者、未使用过抗TNF-α药物患者及既往使用过患者中临床缓解排名均第一。
  • 英夫利西单抗10 mg/kg在内镜改善方面排名第一,乌帕替尼45 mg每日一次第二,英夫利西单抗5 mg/kg第三。
  • 乌帕替尼更易导致不良事件,但严重不良事件未增加,因不良事件停药显著低于安慰剂。

核心结论

  • 在中重度活动性溃疡性结肠炎的网络Meta分析中,乌帕替尼45 mg每日一次在全部患者、未使用过抗TNF-α药物患者及既往使用过患者中临床缓解均排名第一。
  • 英夫利西单抗10 mg/kg在内镜改善方面排名第一。
  • 多数药物安全且耐受良好。

研究设计与样本

  • 系统评价与网状Meta分析,检索文献至2021年10月,纳入28项试验共12504例患者。
  • 采用随机效应模型,以合并相对风险(RR)及95%CI报告数据,干预措施按P-score排名。
  • 疗效判定依据临床缓解、内镜改善或临床应答,并按既往是否暴露于抗TNF-α治疗分层分析。

主要发现

  • 基于未达到临床缓解,乌帕替尼45 mg每日一次对比安慰剂排名第一(RR 0.73;95%CI 0.68至0.80,P-score 0.98),英夫利西单抗5 mg/kg和10 mg/kg分别排名第二和第三。
  • 乌帕替尼在未使用过抗TNF-α药物患者(RR 0.69;95%CI 0.61至0.78,P-score 0.99)和既往暴露患者(RR 0.78;95%CI 0.72至0.85,P-score 0.99)中临床缓解均排名第一,且在这些分析中优于几乎所有其他药物。
  • 基于未达到内镜改善,英夫利西单抗10 mg/kg排名第一(RR 0.61;95%CI 0.51至0.72,P-score 0.97),乌帕替尼45 mg每日一次排名第二,英夫利西单抗5 mg/kg排名第三。
  • 乌帕替尼更易导致不良事件,但严重不良事件未更频繁,因不良事件停药显著低于安慰剂。
  • 与安慰剂相比,托法替布感染风险显著更高(RR 1.41;95%CI 1.03至1.91)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Biological therapies and small molecules continue to be evaluated in moderate to severely active ulcerative colitis, but are often studied in placebo-controlled trials, meaning their relative efficacy and safety is unknown. We examined this in a network meta-analysis. DESIGN: We searched the literature to October 2021 to identify eligible trials. We judged efficacy using clinical remission, endoscopic improvement, or clinical response, and according to previous exposure or non-exposure to antitumour necrosis factor (TNF)-α therapy. We also assessed safety. We used a random effects model and reported data as pooled relative risks (RRs) with 95% CIs. Interventions were ranked according to their P-score. RESULTS: We identified 28 trials (12 504 patients). Based on failure to achieve clinical remission, upadacitinib 45 mg once daily ranked first versus placebo (RR 0.73; 95% CI 0.68 to 0.80, P-score 0.98), with infliximab 5 mg/kg and 10 mg/kg second and third, respectively. Upadacitinib ranked first for clinical remission in both patients naïve to anti-TNF-α drugs (RR 0.69; 95% CI 0.61 to 0.78, P-score 0.99) and previously exposed (RR 0.78; 95% CI 0.72 to 0.85, P-score 0.99). Upadacitinib was superior to almost all other drugs in these analyses. Based on failure to achieve endoscopic improvement infliximab 10 mg/kg ranked first (RR 0.61; 95% CI 0.51 to 0.72, P-score 0.97), with upadacitinib 45 mg once daily, second, and infliximab 5 mg/kg third. Upadacitinib was more likely to lead to adverse events, but serious adverse events were no more frequent, and withdrawals due to adverse events were significantly lower than with placebo. Infections were significantly more likely with tofacitinib than placebo (RR 1.41; 95% CI 1.03 to 1.91). CONCLUSION: In a network meta-analysis, upadacitinib 45 mg once daily ranked first for clinical remission in all patients, patients naïve to anti-TNF-α drugs and patients previously exposed. Infliximab 10 mg/kg ranked first for endoscopic improvement. Most drugs were safe and well tolerated.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Burr NE, Gracie DJ, Black CJ, et al. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. Gut. 2021. PMID: 34937767. doi:10.1136/gutjnl-2021-326390

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。